HeartofDanielle

You cannot commit genocide in Gaza, invade Lebanon, bomb Iran, Syria, Yemen, and Iraq, violate Geneva and Vienna Conventions, international law, human rights, and state sovereignty, then hide behind anti-Semitism. There is no rise in anti-Semitism. There is a rise in the number of people who are very angry at what Israel is doing. Your inability to separate the two is equally problematic.

Patient says “I’m a tea lover… 7–8 cups daily.” How would you explain this link in the simplest way?

Lactobacillus crispatus is in the news since this billionaire decided to study his girlfriend's flora and claimed it to be in the global top 1%. His findings cannot be denied entirely. Scientists have studied this and found that the lactic acid produced by it can inactivate HIV in laboratory settings (in vitro). Later studies have confirmed that vaginal health is not about diversity but about dominance — dominance of a single species of bacteria called Lactobacillus crispatus. In 1953, two French microbiologists named Brygoo and Aladame isolated a small, curled bacterium and gave it the Latin name crispatus, meaning curled. For decades it was largely ignored. Then came the genomics revolution, and with it, a startling realisation: this quiet organism was, in fact, the guardian of the female reproductive tract. In 2011, Jacques Ravel and colleagues sequenced the vaginal bacteria of nearly four hundred women and discovered that the healthiest vaginas were not the most diverse. They were the ones dominated by a single species, Lactobacillus crispatus. This bacterium produces lactic acid and surface proteins that work together in two ways. It lowers the vaginal environment to a pH so acidic that HIV, herpes simplex virus, and bacterial pathogens struggle to survive. It also releases proteins that actively calm local inflammation rather than merely suppress it. Women colonised by this organism have lower rates of bacterial vaginosis, sexually transmitted infections, and preterm birth. A clinical trial published recently showed that it even helped clear high-risk human papillomavirus, the virus responsible for most cervical cancers. Scientists are now exploring the therapeutic potential of this bacterium. The leading candidate, LACTIN-V, contains live L. crispatus CTV-05 and has already demonstrated in a randomised controlled trial that it significantly reduces bacterial vaginosis recurrence. Trials are now underway for preterm birth prevention, HIV risk reduction, and HPV clearance, with a phase 3 study planned and potential regulatory approval on the horizon. What began as a footnote in a 1953 taxonomy paper may become one of the most important therapeutic tools in women's health.